Research describes blood disorders and their impact on Ebola patient outcomes

Research describes blood disorders and their impact on Ebola patient outcomes

Announcing a new article publication forZoonosesMagazine. Hematologic disorders are common in patients with Ebola virus disease (EVD) and are characterized by one or more abnormalities in blood cells, including poorly documented hemostasis. This study described the hematological abnormalities of Ebola patients and the impact on outcomes of patients admitted with EVD.

This was a retrospective observational study of patients recruited from Ebola treatment centers in Butembo and Katwa from February 1, 2019 to June 25, 2020. Clinical and hemogram parameters at the time of admission and outcomes were collected. Descriptive statistics and logistic regressions were performed at a significance level of 0.05. Analyzes were performed using RSTUDIO software.

Of 299 patients hospitalized during the study period, only 129 were included in the analysis. The mean age was 29.9 ± 18.6 years, with a female to male ratio of 1.2. Only 13 patients (10%) were vaccinated against theEbolazaireVirus. Hematologic abnormalities included anemia (55.8%), hyperleukocytosis (36.4%), leukopenia (3.1%), thrombocytopenia (32.6%), and thrombocytosis (30.2%).

Only anemia was statistically significantly correlated with increased viral load. Anemia (OR, 4.07; 95% CI, 1.59-11.3) was found to be an independent risk factor for mortality in patients with EVD based on multivariate analysis. EVD is responsible for important hematological abnormalities that contribute to increased patient mortality.

Sources: